245 related articles for article (PubMed ID: 28913853)
1. Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis.
Ogungbenro K; Patel A; Duncombe R; Nuttall R; Clark J; Lorigan P
Clin Pharmacol Ther; 2018 Apr; 103(4):582-590. PubMed ID: 28913853
[TBL] [Abstract][Full Text] [Related]
2. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Hall E; Zhang J; Kim EJ; Hwang G; Chu G; Bhatia S; Reddy S
Cancer Med; 2020 Mar; 9(6):2106-2112. PubMed ID: 31994335
[TBL] [Abstract][Full Text] [Related]
3. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
Bayle A; Besse B; Annereau M; Bonastre J
Eur J Cancer; 2019 May; 113():28-31. PubMed ID: 30965212
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Ahamadi M; Freshwater T; Prohn M; Li CH; de Alwis DP; de Greef R; Elassaiss-Schaap J; Kondic A; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):49-57. PubMed ID: 27863186
[TBL] [Abstract][Full Text] [Related]
8. A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
Goldstein DA; Gordon N; Davidescu M; Leshno M; Steuer CE; Patel N; Stemmer SM; Zer A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059432
[TBL] [Abstract][Full Text] [Related]
9. Follow up survey for implementation of fixed-dosing of monoclonal antibodies.
Heinhuis KM; Beijnen JH; Hendrikx JJMA
Int J Clin Pharm; 2020 Feb; 42(1):3-6. PubMed ID: 32026351
[TBL] [Abstract][Full Text] [Related]
10. Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question.
Sureda M; Calvo E; Mata JJ; Escudero-Ortiz V; Martinez-Navarro E; Catalán A; Rebollo J
Clin Transl Oncol; 2021 Aug; 23(8):1511-1519. PubMed ID: 33583005
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
12. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.
Pluim D; Ros W; van Bussel MTJ; Brandsma D; Beijnen JH; Schellens JHM
J Pharm Biomed Anal; 2019 Feb; 164():128-134. PubMed ID: 30368118
[TBL] [Abstract][Full Text] [Related]
13. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
da Veiga CRP; da Veiga CP; Drummond-Lage AP
Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
[TBL] [Abstract][Full Text] [Related]
14. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
15. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.
Liu C; Yu J; Li H; Liu J; Xu Y; Song P; Liu Q; Zhao H; Xu J; Maher VE; Booth BP; Kim G; Rahman A; Wang Y
Clin Pharmacol Ther; 2017 May; 101(5):657-666. PubMed ID: 28182273
[TBL] [Abstract][Full Text] [Related]
16. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
Fessas P; Lee H; Ikemizu S; Janowitz T
Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212
[TBL] [Abstract][Full Text] [Related]
17. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
18. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
Tartari F; Santoni M; Burattini L; Mazzanti P; Onofri A; Berardi R
Cancer Treat Rev; 2016 Jul; 48():20-4. PubMed ID: 27310708
[TBL] [Abstract][Full Text] [Related]
19. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
